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The KCL024 human embryonic stem cell line was derived from an embryo donated for research that carried an
autosomal dominant mutation in the NF1 gene encoding neuroﬁbromin (c.3739–3742 ΔTTTG). Mutations in
this gene have been linked to neuroﬁbromatosis type 1, juvenile myelomonocytic leukemia and Watson syn-
drome. The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts.
Both the derivation and cell line propagation were performed in an animal product-free environment. Pluripo-
tent state and differentiation potential were conﬁrmed by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Resource table
Name of stem cell line KCL024
Institution King's College London, London UK
Derivation team Neli Kadeva, Victoria Wood, Glenda Cornwell, Stefano
Codognotto, Emma Stephenson
Contact person and email Dusko Ilic, email: dusko.ilic@kcl.ac.uk
Date archived/stock date Mar. 31, 2011
Type of resource Biological reagent: cell line
Sub-type Human pluripotent stem cell line
Origin Human embryo
Key marker expression Pluripotent stem cell markers: NANOG, OCT4, TRA-1-60,
TRA-1-81, alkaline phosphatase (AP) activity
Authentication Identity and purity of line conﬁrmed
Link to related literature
(direct URL links and
full references)
1) Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson,
D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H.,
Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012.
Derivation and feeder-free propagation of human
embryonic stem cells under xeno-free conditions.
Cytotherapy. 14 (1), 122–128.
doi: 10.3109/14653249.2011.623692
http://www.ncbi.nlm.nih.gov/pubmed/22029654
2) Stephenson, E., Jacquet, L., Miere, C., Wood, V.,
Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y.,
Braude, P., Ilic, D., 2012. Derivation and
propagation of human embryonic stem cell lines
from frozen embryos in an animal product-free
environment. Nat. Protoc. 7 (7), 1366–1381.
doi: 10.1038/nprot.2012.080
http://www.ncbi.nlm.nih.gov/pubmed/22722371
Information in public
databases
KCL024 is a National Institutes of Health (NIH)
registered hESC line
NIH Registration Number: 0220
NIH Approval Number: NIHhESC-13-0220
http://grants.nih.gov/stem_cells/
registry/current.htm?id=660
Ethics The hESC line KCL024 is derived under license from the
UK Human Fertilisation and Embryology Authority
(research license numbers: R0075 and R0133) and also
has local ethical approval (UK National Health Service
Research Ethics Committee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and
the experiments conformed to the principles set out in
the WMA Declaration of Helsinki and the NIH Belmont
Report. No
ﬁnancial inducements are offered for donation.
Resource details
Consent signed Oct. 28, 2010
Embryo used Mar. 03, 2011
UK Stem Cell Bank Deposit Approval Dec. 01, 2011
Reference: SCSC11-48
Sex ND
Grade Research
Disease status (Fig 1) Autosomal dominant mutation in the NF1 gene
encoding neuroﬁbromin (c.3739–3742 ΔTTTG)
Karyotype (aCGH) ND
DNA ﬁngerprint ND
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E-mail address: dusko.ilic@kcl.ac.uk (D. Ilic).
http://dx.doi.org/10.1016/j.scr.2016.01.010
1873-5061/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Genetic pedigree tree. Male donor was carrying an autosomal dominant
mutation c.3739–3742 ΔTTTG in the NF1 gene. The couple undergoing IVF and
prenatal genetic diagnosis had 6 embryos in this particular cycle. Embryos carrying
the mutation in the NF1 gene were donated for research. We derived two hESC
lines: KCL024 and KCL025.
Fig. 2. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar,
50 μm.
HLA typing HLA-A: 11,32; -B: 35,55; -C 03,15; DRB1:
04,11
Viability testing Pass
Pluripotent markers
(immunostaining) (Fig 2)
NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layers differentiation
in vitro (immunostaining) (Fig 3)
Endoderm: AFP (α-fetoprotein)
Ectoderm: TUBB3 (tubulin, β3 class III)
Mesoderm: ACTA2 (actin, α2, smooth muscle)
Sibling lines available KCL025
ND, not determined.
We generated KCL024 clinical grade hESC line following proto-
cols, established previously (Ilic et al., 2012; Stephenson et al.,
2012). The expression of the pluripotency markers was tested after
freeze/thaw cycle. Differentiation potential into three germ layers
was veriﬁed in vitro.
Materials and methods
Consenting process
Wedistribute Patient Information Sheet (PIS) and consent form to the
in vitro fertilization (IVF) patients if they opted to donate to research em-
bryos that were stored for 5 or 10 years. Theymail signed consent back to
us and that might be months after the PIS and consent were mailed to
them. If in the meantime new versions of PIS/consent are implemented,
we do not send these to the patients or ask them to re-sign; the whole
process is done with the version that was given them initially. The PIS/
consent documents (PGD-V.8) were created on Jul. 01, 2010. HFEA
Code of Practice that was in effect at the time of document creation: Edi-
tion 8 — R.2 (http://www.hfea.gov.uk/2999.html). The donor couple
signed the consent on Oct. 28, 2010. HFEA Code of Practice that was in ef-
fect at the time of donor signature: Edition 8— R.2. HFEA Code of Practice
Edition 8— R.2 was in effect 07 Apr. 2010–Apr. 06, 2011.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC colo-
nies were expanded and cryopreserved at the third passage.
Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
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up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro as described (Ilic et al., 2012; Stephenson et al., 2012; Petrova
et al., 2014).
HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
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Fig. 3. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm andα-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 100 μm.
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